A Study of Nivolumab Immunotherapy and Chemotherapy followed by Surgery for Pleural Mesothelioma

Share
Print

Full Title

Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma

Purpose

The purpose of this study is to see if nivolumab immunotherapy given in combination with chemotherapy (pemetrexed and either cisplatin or carboplatin) before surgery safe and effective for treating operable pleural mesothelioma without delaying surgery. Nivolumab works by boosting the power of the immune system to find and kill cancer cells.

Pemetrexed, cisplatin, and carboplatin are already used in the treatment of mesothelioma; their use in combination with nivolumab for mesothelioma is considered investigational. These medications are all given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have pleural mesothelioma that has not been previously treated with chemotherapy or immunotherapy.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Marjorie Zauderer at 646-888-4656.

Protocol

19-272

Phase

I

Disease Status

Newly Diagnosed

Investigator

Co-Investigators

Diseases